Icia Santos-Zas

Icia Santos-Zas

Auto-generated profile, based on publicly available information

Icia Santos-Zas

Laboratorio de Endocrinología Celular, Área de Endocrinología Molecular y Cellular Instituto de Investigación Sanitaria de Santiago, Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ISIcia Santos-Zas
Icia Santos-Zas
JLJeremie Lemarié
Jeremie Lemarié
IZIvana Zlatanova
Ivana Zlatanova
MCMarine Cachanado
Marine Cachanado
JSJean-Christophe Seghezzi
Jean-Christophe Seghezzi
HOHafid Ait Oufella
Hafid Ait Oufella
Acute myocardial infarction is a common condition responsible for heart failure and sudden death. Here, we show that following acute myocardial infarction in mice, CD8+T lymphocytes are recruited and activated in the ischemic heart tissue and release Granzyme B, leading to cardiomyocyte apoptosis, adverse ventricular remodeling and deterioration of myocardial function. Depletion of CD8+T lymphocytes decreases apoptosis within the ischemic myocardium, hampers inflammatory response, limits myocardial injury and improves heart function. These effects are recapitulated in mice withGranzyme B-deficient CD8+T cells. The protective effect of CD8 depletion on heart function is confirmed by using a model of ischemia/reperfusion in pigs. Finally, we reveal that elevated circulating levels of GRANZYME B in patients with acute myocardial infarction predict increased risk of death at 1-year follow-up. Our work unravels a deleterious role of CD8+T lymphocytes following acute ischemia, and suggests potential therapeutic strategies targeting pathogenic CD8+T lymphocytes in the setting of acute myocardial infarction.

20 May 2019 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
ALAdrien Lupieri
Adrien Lupieri
NSNatalia F Smirnova
Natalia F Smirnova
RSRomain Solinhac
Romain Solinhac
NMNicole Malet
Nicole Malet
MBMehdi Benamar
Mehdi Benamar
MLMuriel Laffargue
Muriel Laffargue
Defects in efficient endothelial healing have been associated with complication of atherosclerosis such as post-angioplasty neoatherosclerosis and plaque erosion leading to thrombus formation. However, current preventive strategies do not consider re-endothelialization in their design. Here, we investigate mechanisms linking immune processes and defect in re-endothelialization. We especially evaluate if targeting phosphoinositide 3-kinase γ immune processes could restore endothelial healing and identify immune mediators responsible for these defects. Using in vivo model of endovascular injury, we showed that both ubiquitous genetic inactivation of PI3Kγ and hematopoietic cell-specific PI3Kγ deletion improved re-endothelialization and that CD4+ T-cell population drives this effect. Accordingly, absence of PI3Kγ activity correlates with a decrease in local IFNγ secretion and its downstream interferon-inducible chemokine CXCL10. CXCL10 neutralization promoted re-endothelialization in vivo as the same level than those observed in absence of PI3Kγ suggesting a role of CXCL10 in re-endothelialization defect. Using a new established ex vivo model of carotid re-endothelialization, we showed that blocking CXCL10 restore the IFNγ-induced inhibition of endothelial healing and identify smooth muscle cells as the source of CXCL10 secretion in response to Th1 cytokine. Altogether, these findings expose an unforeseen cellular cross-talk within the arterial wall whereby a PI3Kγ-dependent T-cell response leads to CXCL10 production by smooth muscle cells which in turn inhibits endothelial healing. Therefore, both PI3Kγ and the IFNγ/CXCL10 axis provide novel strategies to promote endothelial healing.

2 August 2024 in Circulation Research
Verified
Journal Article
Closed access
HQHelene Quelquejay
Helene Quelquejay
RARida Al-Rifai
Rida Al-Rifai
MSMichele Silvestro
Michele Silvestro
MVMarie Vandestienne
Marie Vandestienne
IFIrmine Ferreira
Irmine Ferreira
HOHafid Ait Oufella
Hafid Ait Oufella
BACKGROUND: The long isoform of the Wnk1 (with-no-lysine [K] kinase 1) is a ubiquitous serine/threonine kinase, but its role in vascular smooth muscle cells (VSMCs) pathophysiology remains unknown. METHODS: AngII (angiotensin II) was infused in Apoe −/− to induce experimental aortic aneurysm. Mice carrying an Sm22-Cre allele were cross-bred with mice carrying a floxed Wnk1 allele to specifically investigate the functional role of Wnk1 in VSMCs. RESULTS: Single-cell RNA-sequencing of the aneurysmal abdominal aorta from AngII-infused Apoe −/− mice revealed that VSMCs that did not express Wnk1 showed lower expression of contractile phenotype markers and increased inflammatory activity. Interestingly, WNK1 gene expression in VSMCs was decreased in human abdominal aortic aneurysm. Wnk1 -deficient VSMCs lost their contractile function and exhibited a proinflammatory phenotype, characterized by the production of matrix metalloproteases, as well as cytokines and chemokines, which contributed to local accumulation of inflammatory macrophages, Ly6C hi monocytes, and γδ T cells. Sm22Cre+Wnk1 lox/lox mice spontaneously developed aortitis in the infrarenal abdominal aorta, which extended to the thoracic area over time without any negative effect on long-term survival. AngII infusion in Sm22Cre+Wnk1 lox/lox mice aggravated the aortic disease, with the formation of lethal abdominal aortic aneurysms. Pharmacological blockade of γδ T-cell recruitment using neutralizing anti-CXCL9 (anti-CXC motif chemokine ligand 9) antibody treatment, or of monocyte/macrophage using Ki20227, a selective inhibitor of CSF1 receptor, attenuated aortitis. Wnk1 deletion in VSMCs led to aortic wall remodeling with destruction of elastin layers, increased collagen content, and enhanced local TGF-β (transforming growth factor-beta) 1 expression. Finally, in vivo TGF-β blockade using neutralizing anti-TGF-β antibody promoted saccular aneurysm formation and aorta rupture in Sm22 Cre+ Wnk1 lox/lox mice but not in control animals. CONCLUSION: Wnk1 is a key regulator of VSMC function. Wnk1 deletion promotes VSMC phenotype switch toward a pathogenic proinflammatory phenotype, orchestrating deleterious vascular remodeling and spontaneous severe aortitis in mice.

1 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
RCRaphael Cohen
Raphael Cohen
VDVincent Duval
Vincent Duval
RARida Al-Rifai
Rida Al-Rifai
SMSidrah Maryam
Sidrah Maryam
ISIcia Santos-Zas
Icia Santos-Zas
HOHafid Ait Oufella
Hafid Ait Oufella
Ischemic heart failure remains a major clinical challenge, underscoring the need to better understand post-infarction immune mechanisms and identify new therapeutic targets. Both innate and adaptive immunity contribute to adverse cardiac remodeling following myocardial infarction (MI), yet the role of cytotoxic cells such as natural killer (NK) cells remains poorly defined. Here, we show that after acute MI in mice, NK cells are recruited to the ischemic myocardium in a CCR2-dependent manner and become activated. Activated NK cells locally release granzyme B, promoting cardiomyocyte apoptosis, adverse ventricular remodeling, and impaired cardiac function. Genetic deletion or pharmacological depletion of NK cells reduces cardiomyocyte death, attenuates inflammation, limits myocardial injury, and improves cardiac function. In contrast, NK cell activation using an anti-NKG2A monoclonal antibody exacerbates ischemic heart failure. We further demonstrate that NK cells regulate bone marrow myelopoiesis through local GM-CSF production. Finally, we identify a distinct NK cellular and transcriptomic signature in human ischemic heart tissue at early stages. Together, these findings reveal a detrimental role for NK cells following acute MI and highlight NK cells as potential therapeutic targets to limit adverse cardiac remodeling.

25 November 2025 in Molecular Biomedicine
Verified
Journal Article
Open access
PDF file
ALAndrea C. Lodeiro
Andrea C. Lodeiro
SLSaúl Leal-López
Saúl Leal-López
SCSilvia Costas-Abalde
Silvia Costas-Abalde
LDLucía Debasa-Corral
Lucía Debasa-Corral
MOMaría J. Otero-Fraga
María J. Otero-Fraga
ISIcía Santos-Zas
Icía Santos-Zas

14 January 2026 in Medcomm
Verified
Journal Article
Open access
ISIcía Santos‐Zas
Icía Santos‐Zas
SCSilvia Costas‐Abalde
Silvia Costas‐Abalde
ALAndrea C. Lodeiro
Andrea C. Lodeiro
FFFátima Fernández‐Barreiro
Fátima Fernández‐Barreiro
TCTania Cid‐Díaz
Tania Cid‐Díaz
JCJesus P. Camiña
Jesus P. Camiña
The mechanisms by which muscular dystrophy‐related stress is transduced to the autophagic machinery remain poorly characterized. The formulation of strategies should be based on how disruption of these processes results in the deregulation of signaling pathways that contribute to many pathological effects of the disease. In this study, we investigated the molecular mechanism by which the obestatin/GPR39 system, an autocrine signaling with anabolic impact on normal skeletal muscle, restores autophagy in Duchenne muscular dystrophy (DMD). We report that obestatin integrates 5' AMP‐activated protein kinase (AMPK) and mammalian target of rapamycin complex 1 (mTORC1) signaling to control ubiquitin proteasome system (UPS), autophagy–lysosome system, and protein synthesis under dystrophic context. The posttranslational modifications of the E3 ligase NEDD4‐L emerges as the main switch to activate the autophagy in response to obestatin. This includes NEDD4‐L tyrosine phosphorylation and autoubiquitination, which is critical for recruiting the ubiquitin‐specific protease 10 to assemble a deubiquitination complex, that orchestrates the unc‐51 like autophagy activating kinase 1 (ULK1) and class III PI3K (VPS34) complexes. Reactivation of autophagy through obestatin signaling promotes the recovery of physiological skeletal muscle function. Thus, DMD conditions determine permissiveness to the activation of AMPK that sustain autophagy under anabolic conditions stablished by obestatin signaling through mTORC1.